Relevance of telomere/telomerase system impairment in early stage chronic lymphocytic leukemia

Genes Chromosomes and Cancer

Volumn 53, Issue 7, 2014, Pages 612-621

  Hoxha, Mirjam ^a   Fabris, Sonia ^a   Agnelli, Luca ^a   Bollati, Valentina ^a   Cutrona, Giovanna ^b   Matis, Serena ^b   Recchia, Anna Grazia ^c   Gentile, Massimo ^c   Cortelezzi, Agostino ^a   Morabito, Fortunato ^c   Bertazzi, Pier Alberto ^a   Ferrarini, Manlio ^b   Neri, Antonino ^a  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c Azienda Ospedaliera di Cosenza   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CD19 ANTIGEN; RAD50 PROTEIN; RAP1 PROTEIN; TELOMERASE; TELOMERIC REPEAT BINDING FACTOR 1; TERT PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; B LYMPHOCYTE; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CHROMOSOME 11Q; CHROMOSOME 13Q; CHROMOSOME 17P; CHROMOSOME ANALYSIS; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DNA METHYLATION; FEMALE; GENE; GENE EXPRESSION; GENE MUTATION; GENETIC RISK; HUMAN; LONG INTERSPERSED REPEAT; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MRE11A GENE; OUTCOME ASSESSMENT; PATHOGENESIS; POT1 GENE; PRIORITY JOURNAL; RAD50 GENE; RAP1 GENE; RPA1 GENE; TELOMERE HOMEOSTASIS; TELOMERE SHORTENING; TERT GENE; TRF1 GENE; UPREGULATION; VERY ELDERLY; CASE CONTROL STUDY; GENE EXPRESSION PROFILING; GENETICS; METABOLISM; RETROSPECTIVE STUDY; TELOMERE;

ADULT; AGED; AGED, 80 AND OVER; B-LYMPHOCYTES; CASE-CONTROL STUDIES; DNA METHYLATION; GENE EXPRESSION PROFILING; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MIDDLE AGED; RETROSPECTIVE STUDIES; TELOMERASE; TELOMERE; TELOMERE SHORTENING;

EID: 84899904319     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.22171     Document Type: Article

References (49)

1. Augereau A, t'kint de RC, Simonet T, Bauwens S, Horard B, Callanan M, Leroux D, Jallades L, Salles G, Gilson E, Poncet D. 2011. Telomeric damage in early stage of chronic lymphocytic leukemia correlates with shelterin dysregulation. Blood 118:1316-1322.
2. Binet JL, Lepoprier M, Dighiero G, Charron D, d'Athis P, Vaugier G, Beral HM, Natali JC, Raphael M, Nizet B, Follezou JY. 1977. A clinical staging system for chronic lymphocytic leukemia: Prognostic significance. Cancer 40:855-864.
3. Blackburn EH. 2011. Walking the walk from genes through telomere maintenance to cancer risk. Cancer Prev Res (Phila) 4:473-475.
4. Bochkarev A, Bochkareva E. 2004. From RPA to BRCA2: Lessons from single-stranded DNA binding by the OB-fold. Curr Opin Struct Biol 14:36-42.
5. Brezinova J, Berkova A, Vcelikova S, Zemanova Z, Izakova S, Sarova I, Cechova H, Tajtlova J, Grosova L, Lizcova L, Malinova E, Zemanova M, Cmunt E, Karban J, Trneny M, Schwarz J, Michalova K. 2010. Telomere length, molecular cytogenetic findings, and immunophenotypic features in previously untreated patients with B-chronic lymphocytic leukemia. Neoplasma 57:215-221.
6. Cawthon RM. 2002. Telomere measurement by quantitative PCR. Nucleic Acids Res 30:e47.
7. Chang S. 2013. Cancer chromosomes going to POT1. Nat Genet 45:473-475.
8. Chiorazzi N, Rai KR, Ferrarini M. 2005. Chronic lymphocytic leukemia. N Engl J Med 352:804-815.
9. Cohen SB, Graham ME, Lovrecz GO, Bache N, Robinson PJ, Reddel RR. 2007. Protein composition of catalytically active human telomerase from immortal cells. Science 315:1850-1853.
10. Counter CM, Avilion AA, LeFeuvre CE, Stewart NG, Greider CW, Harley CB, Bacchetti S. 1992. Telomere shortening associated with chromosome instability is arrested in immortal cells, which express telomerase activity. EMBO J 11:1921-1929.
11. Counts JL, Goodman JI. 1995. Alterations in DNA methylation may play a variety of roles in carcinogenesis. Cell 83:13-15.
12. Crespo M, Bosch F, Villamor N, Bellosillo B, Colomer D, Rozman M, Marce S, Lopez-Guillermo A, Campo E, Montserrat E. 2003. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med 348:1764-1775.
13. Damle RN, Batliwalla FM, Ghiotto F, Valetto A, Albesiano E, Sison C, Allen SL, Kolitz J, Vinciguerra VP, Kudalkar P, Wasil T, Rai KR, Ferrarini M, Gregersen PK, Chiorazzi N. 2004. Telomere length and telomerase activity delineate distinctive replicative features of the B-CLL subgroups defined by immunoglobulin V gene mutations. Blood 103:375-382.
14. Damle RN, Wasil T, Fais F, Ghiotto F, Valetto A, Allen SL, Buchbinder A, Budman D, Dittmar K, Kolitz J, Lichtman SM, Schulman P, Vinciguerra VP, Rai KR, Ferrarini M, Chiorazzi N. 1999. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 94:1840-1847.
15. Dohner H, Stilgenbauer S, Dohner K, Bentz M, Lichter P. 1999. Chromosome aberrations in B-cell chronic lymphocytic leukemia: Reassessment based on molecular cytogenetic analysis. J Mol Med (Berl) 77:266-281.
16. Dohner H, Stilgenbauer S, Benner A, Leupolt E, Krober A, Bullinger L, Dohner K, Bentz M, Lichter P. 2000. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 343:1910-1916.
17. Fabris S, Bollati V, Agnelli L, Morabito F, Motta V, Cutrona G, Matis S, Grazia RA, Gigliotti V, Gentile M, Deliliers GL, Bertazzi PA, Ferrarini M, Neri A, Baccarelli A. 2011. Biological and clinical relevance of quantitative global methylation of repetitive DNA sequences in chronic lymphocytic leukemia. Epigenetics 6:188-194.
18. Fabris S, Mosca L, Cutrona G, Lionetti M, Agnelli L, Ciceri G, Barbieri M, Maura F, Matis S, Colombo M, Gentile M, Recchia AG, Anna PE, Di RF, Musolino C, Gobbi M, Di RN, Mauro FR, Brugiatelli M, Ilariucci F, Lipari MG, Angrilli F, Consoli U, Fragasso A, Molica S, Festini G, Vincelli I, Cortelezzi A, Federico M, Morabito F, Ferrarini M, Neri A. 2013. Chromosome 2p gain in monoclonal B-cell lymphocytosis and in early stage chronic lymphocytic leukemia. Am J Hematol 88:24-31.
19. Givalos N, Gakiopoulou H, Skliri M, Bousboukea K, Konstantinidou AE, Korkolopoulou P, Lelouda M, Kouraklis G, Patsouris E, Karatzas G. 2007. Replication protein A is an independent prognostic indicator with potential therapeutic implications in colon cancer. Mod Pathol 20:159-166.
20. Goeman JJ, Van De Geer SA, Van Houwelingen HC. 2006. Testing against a high dimensional alternative. J R Stat Soc Ser B (Statistical Methodology) 68:477-493.
21. Grabowski P, Hultdin M, Karlsson K, Tobin G, Aleskog A, Thunberg U, Laurell A, Sundstrom C, Rosenquist R, Roos G. 2005. Telomere length as a prognostic parameter in chronic lymphocytic leukemia with special reference to VH gene mutation status. Blood 105:4807-4812.
22. Hackett JA, Greider CW. 2002. Balancing instability: Dual roles for telomerase and telomere dysfunction in tumorigenesis. Oncogene 21:619-626.
23. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. 1999. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 94:1848-1854.
24. Hamblin TJ, Orchard JA, Ibbotson RE, Davis Z, Thomas PW, Stevenson FK, Oscier DG. 2002. CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease. Blood 99:1023-1029.
25. Harley CB, Futcher AB, Greider CW. 1990. Telomeres shorten during ageing of human fibroblasts. Nature 345:458-460.
26. La TD, Conti A, Aguennouz MH, De Pasquale MG, Romeo S, Angileri FF, Cardali S, Tomasello C, Alafaci C, Germano A. 2013. Telomere length modulation in human astroglial brain tumors. PLoS One 8:e64296.
27. Loayza D, De Lange T. 2003. POT1 as a terminal transducer of TRF1 telomere length control. Nature 423:1013-1018.
28. Mansouri L, Grabowski P, Degerman S, Svenson U, Gunnarsson R, Cahill N, Smedby KE, Geisler C, Juliusson G, Roos G, Rosenquist R. 2013. Short telomere length is associated with NOTCH1/SF3B1/TP53 aberrations and poor outcome in newly diagnosed chronic lymphocytic leukemia patients. Am J Hematol 88:647-651.
29. Matsutani N, Yokozaki H, Tahara E, Tahara H, Kuniyasu H, Kitadai Y, Haruma K, Chayama K, Tahara E, Yasui W. 2001. Expression of MRE11 complex (MRE11, RAD50, NBS1) and hRap1 and its relation with telomere regulation, telomerase activity in human gastric carcinomas. Pathobiology 69:219-224.
30. McGrath M, Wong JY, Michaud D, Hunter DJ, De VI. 2007. Telomere length, cigarette smoking, and bladder cancer risk in men and women. Cancer Epidemiol Biomarkers Prev 16:815-819.
31. Morabito F, Cutrona G, Gentile M, Matis S, Todoerti K, Colombo M, Sonaglio C, Fabris S, Reverberi D, Megna M, Spriano M, Lucia E, Rossi E, Callea V, Mazzone C, Festini G, Zupo S, Molica S, Neri A, Ferrarini M. 2009. Definition of progression risk based on combinations of cellular and molecular markers in patients with Binet stage a chronic lymphocytic leukaemia. Br J Haematol 146:44-53.
32. Morin GB. 1989. The human telomere terminal transferase enzyme is a ribonucleoprotein that synthesizes TTAGGG repeats. Cell 59:521-529.
33. O'Connor MS, Safari A, Liu D, Qin J, Songyang Z. 2004. The human Rap1 protein complex and modulation of telomere length. J Biol Chem 279:28585-28591.
34. Oh BK, Kim YJ, Park C, Park YN. 2005. Up-regulation of telomere-binding proteins, TRF1, TRF2, and TIN2 is related to telomere shortening during human multistep hepatocarcinogenesis. Am J Pathol 166:73-80.
35. Palm W, de Lange T. 2008. How shelterin protects mammalian telomeres. Annu Rev Genet 42:301-334.
36. Poncet D, Belleville A, t'kint de RC, Roborel de CA, Ben SE, Merle-Beral H, Callet-Bauchu E, Salles G, Sabatier L, Delic J, Gilson E. 2008. Changes in the expression of telomere maintenance genes suggest global telomere dysfunction in B-chronic lymphocytic leukemia. Blood 111:2388-2391.
37. Poole JC, Andrews LG, Tollefsbol TO. 2001. Activity, function, and gene regulation of the catalytic subunit of telomerase (TERT). Gene 269:1-12.
38. Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS. 1975. Clinical staging of chronic lymphocytic leukemia. Blood 46:219-234.
39. Rampazzo E, Bonaldi L, Trentin L, Visco C, Keppel S, Giunco S, Frezzato F, Facco M, Novella E, Giaretta I, Del BP, Semenzato G, De RA. 2012. Telomere length and telomerase levels delineate subgroups of B-cell chronic lymphocytic leukemia with different biological characteristics and clinical outcomes. Haematologica 97:56-63.
40. Ricca I, Rocci A, Drandi D, Francese R, Compagno M, Lobetti BC, De MF, Astolfi M, Monitillo L, Vallet S, Calvi R, Ficara F, Omede P, Rosato R, Gallamini A, Marinone C, Bergui L, Boccadoro M, Tarella C, Ladetto M. 2007. Telomere length identifies two different prognostic subgroups among VH-unmutated B-cell chronic lymphocytic leukemia patients. Leukemia 21:697-705.
41. Roos G, Krober A, Grabowski P, Kienle D, Buhler A, Dohner H, Rosenquist R, Stilgenbauer S. 2008. Short telomeres are associated with genetic complexity, high-risk genomic aberrations, and short survival in chronic lymphocytic leukemia. Blood 111:2246-2252.
42. Rossi D, Lobetti BC, Genuardi E, Monitillo L, Drandi D, Cerri M, Deambrogi C, Ricca I, Rocci A, Ferrero S, Bernocco E, Capello D, De PL, Bergui L, Boi M, Omede P, Massaia M, Tarella C, Passera R, Boccadoro M, Gaidano G, Ladetto M. 2009. Telomere length is an independent predictor of survival, treatment requirement and Richter's syndrome transformation in chronic lymphocytic leukemia. Leukemia 23:1062-1072.
43. Salhab M, Jiang WG, Newbold RF, Mokbel K. 2008. The expression of gene transcripts of telomere-associated genes in human breast cancer: Correlation with clinico-pathological parameters and clinical outcome. Breast Cancer Res Treat 109:35-46.
44. Sellmann L, de BD, Bartels M, Opalka B, Nuckel H, Duhrsen U, Durig J, Seifert M, Siemer D, Kuppers R, Baerlocher GM, Roth A. 2011. Telomeres and prognosis in patients with chronic lymphocytic leukaemia. Int J Hematol 93:74-82.
45. Stansel RM, de LT, Griffith JD. 2001. T-loop assembly in vitro involves binding of TRF2 near the 3′ telomeric overhang. EMBO J 20:5532-5540.
46. Terrin L, Trentin L, Degan M, Corradini I, Bertorelle R, Carli P, Maschio N, Bo MD, Noventa F, Gattei V, Semenzato G, De RA. 2007. Telomerase expression in B-cell chronic lymphocytic leukemia predicts survival and delineates subgroups of patients with the same igVH mutation status and different outcome. Leukemia 21:965-972.
47. Vera E, Canela A, Fraga MF, Esteller M, Blasco MA. 2008. Epigenetic regulation of telomeres in human cancer. Oncogene 27:6817-6833.
48. Veronese L, Tournilhac O, Callanan M, Prie N, Kwiatkowski F, Combes P, Chauvet M, Davi F, Gouas L, Verrelle P, Guieze R, Vago P, Bay JO, Tchirkov A. 2013. Telomeres and chromosomal instability in chronic lymphocytic leukemia. Leukemia 27:490-493.
49. Wilson AS, Power BE, Molloy PL. 2007. DNA hypomethylation and human diseases. Biochim Biophys Acta 1775:138-162.